1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1326,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1326,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1326,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1326,
2002,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Gemfibrozil highly cost-effective in CHD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1326,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Best case needed to see oseltamivir's value for flu in Canada |
|
Inpharma Weekly,
Volume &NA;,
Issue 1326,
2002,
Page 7-8
Laura Hunt,
Preview
|
|
摘要:
Influenza deals society a harsh blow with its significant annual incidence of morbidity and mortality. The majority of hospitalisations, and the associated costs, can be attributed to patients with chronic underlying disease, regardless of age. The neuraminidase inhibitor oseltamivir ['Tamiflu'] is a new treatment for influenza, and the second such therapy to be approved for use in Canada.*However, a recent report by the Canadian Coordinating Office for Health Technology Assessment (CCOHTA) concluded that oseltamivir is only likely to be cost effective for the treatment of influenza in Canada under very favourable conditions.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1326,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1326,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
Doxorubicin-based regimens beneficial in DLCL |
|
Inpharma Weekly,
Volume &NA;,
Issue 1326,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Donepezil effective in vascular dementia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1326,
2002,
Page 11-12
Raewyn Poole,
Preview
|
|
摘要:
The acetylcholinesterase inhibitor donepezil ['Aricept'] is effective in the treatment of vascular dementia, according to results from a phase III study (trial 308) presented at the 2nd International Congress on Vascular Dementia [Salzburg, Austria; January 2002]. Cognitive and global function was significantly improved in donepezil recipients in this placebo-controlled study, the first to be conducted exclusively in patients with vascular dementia.1The study's presenter, Dr Raymond Pratt, senior director of clinical research at Eisai Inc., commented that'these results suggest[donepezil]may be a promising option in treating VaD[vascular dementia] -a condition for which there is currently no approved treatment'.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|